James Investment Research’s ARK Genomic Revolution ETF ARKG Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2022
Q1
Sell
-3,791
Closed -$232K 501
2021
Q4
$232K Sell
3,791
-2,450
-39% -$169K 0.02% 276
2021
Q3
$466K Sell
6,241
-29,019
-82% -$2.43M 0.04% 201
2021
Q2
$3.26M Sell
35,260
-2,039
-5% -$173K 0.28% 96
2021
Q1
$3.31M Sell
37,299
-7,748
-17% -$769K 0.3% 96
2020
Q4
$4.2M Buy
45,047
+2,469
+6% +$197K 0.38% 83
2020
Q3
$2.71M Buy
42,578
+6,472
+18% +$379K 0.25% 104
2020
Q2
$1.88M Buy
+36,106
New +$1.55M 0.18% 116

Other funds holding ARKG

James Investment Research's ARKG Position: Q1 2022 in Review

James Investment Research sold out of ARK Genomic Revolution ETF (ARKG) in Q1 2022, closing a stake of 3,791 shares — an estimated $232K sold.

James Investment Research first reported a position in ARKG in Q2 2020 and held it in 7 quarters. The position peaked at $4.2M in Q4 2020. 387 funds tracked by Wall St. Rank hold ARKG as of Q1 2022.

  • James Investment Research reported no remaining ARK Genomic Revolution ETF position as of Q1 2022 after selling out during the quarter.
  • James Investment Research sold 3,791 ARK Genomic Revolution ETF shares in Q1 2022, an estimated $232K.
  • James Investment Research first reported a position in ARK Genomic Revolution ETF in Q2 2020 and held it in 7 quarters.
  • James Investment Research's ARK Genomic Revolution ETF position peaked at $4.2M in Q4 2020.
  • 387 funds tracked by Wall St. Rank held ARK Genomic Revolution ETF as of Q1 2022.

Based on James Investment Research's 13F filing for Q1 2022, filed 22 Apr 2022.